We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
On July 18, 2021, ImmVira inaugurated a pilot-scale production line in Shenzhen and officially initiated its in-house production of our next-generation oncolytic viruses (OV) used for IND applications and Phase I/II clinical trials.